1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Connecticut >
  6. Johnson & Johnson Acquires Halda Therapeutics

M&A Deal Summary

Johnson & Johnson Acquires Halda Therapeutics

On November 17, 2025, Johnson & Johnson acquired life science company Halda Therapeutics for 3.1B USD

Acquisition Highlights
  • This is Johnson & Johnson’s 20th transaction in the Life Science sector.
  • This is Johnson & Johnson’s 11th largest (disclosed) transaction.
  • This is Johnson & Johnson’s 39th transaction in the United States.
  • This is Johnson & Johnson’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2025-11-17
Target Halda Therapeutics
Sector Life Science
Buyer(s) Johnson & Johnson
Deal Type Add-on Acquisition
Deal Value 3.1B USD

Target

Halda Therapeutics

New Haven, Connecticut, United States
Halda Therapeutics is a clinical-stage biotechnology company developing a novel class of cancer therapies based on its proprietary RIPTAC (Regulated Induced Proximity Targeting Chimeras) platform. The RIPTAC modality works via a “hold-and-kill” mechanism, binding a tumor-specific protein and an essential cellular protein to trigger selective cancer-cell death. Halda Therapeutics is based in New Haven, Connecticut

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Johnson & Johnson

New Brunswick, New Jersey, United States
Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 88.8B USD (2024)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 47 of 47
Sector: Life Science M&A 20 of 20
Type: Add-on Acquisition M&A Deals 39 of 39
State: Connecticut M&A 1 of 1
Country: United States M&A 39 of 39
Year: 2025 M&A 2 of 2
Size (of disclosed) 11 of 31
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-01-13 Intra-Cellular Therapies

Bedminster, New Jersey, United States

Intra-Cellular Therapies is a biopharmaceutical company. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. Intra-Cellular Therapies was founded in 2002 and is based in Bedminster, New Jersey.

Buy $14.6B
Mergr

Solution for

Product

Company

Legal